Unichem Labs. (UNICHEMLAB)

FairStock Score: 35/100 — MIXED

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Low debt-to-equity of 0.21 provides financial cushion in a weak earnings phase.
• Promoter holding of 70.22% indicates strong ownership alignment.
• Price-to-book of 1.14 means the stock is not far from tangible book value of ₹338.54.
• Sales decline of only 2.24% suggests the business hasn't suffered a demand collapse.
• Latest quarter net profit of ₹264 Cr on ₹521 Cr sales, if sustainable or one-off, could unlock value.

Concerns

• Profit growth has crashed by 69.96%, showing severe deterioration in earning power.
• Piotroski F-Score of 3/9 and FairStock Score of 1/100 flag poor financial health and high risk.
• P/E of 23.17 on declining earnings is not a margin of safety.
• ROE of 9.56% and ROCE of 6.24% are mediocre, and the zero dividend offers no income support.

AI Analysis

Let me start with what I see: a pharmaceutical business with a FairStock Score of 1 and a Piotroski F-Score of 3. That already tells me the recent fundamentals are weak. Unichem's sales fell 2.24% and profits crashed 69.96%. No amount of industry tailwind can excuse that kind of earnings collapse in a stable pharma market. The stock is at ₹385.40, against book value of ₹338.54, so I am paying a 14% premium to tangible net assets. Historically, I have no problem holding a good business at fair price, but I do not yet see evidence of a good business here. ROE is only 9.56% and ROCE 6.24%; both are below what I expect from a company with pricing power. The balance sheet is respectable—debt/equity 0.21—and promoters own 70.22%, which aligns owners and management. Yet no dividend is paid, so the shareholder is entirely dependent on capital gains. The latest quarter shows net profit of ₹264 Cr on sales of ₹521 Cr; that is an unusually high margin and I would immediately ask whether it comes from recurring operations or a one-time gain. Since annual profit growth is -69.96%, the quarterly number clearly is not the norm. A P/E of 23.17 on falling earnings is not a margin of safety. The shares have fallen from ₹687.20 to around ₹385.40, but a lower price does not automatically make it cheap. I need to see stable profit margins, a rebound in sales growth, and better returns on capital before I can call this a Graham-style investment. Right now it has more of the smell of a speculative turnaround than a concrete value proposition.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer